Impact of Bronchodilator Responsiveness on Quality of Life and Exercise Capacity in Patients With COPD

References

1. 1.↵
   1. Rabe KF,
   2. Hurd S,
   3. Anzueto A,
   4. Barnes PJ,
   5. Buist AS,
   6. Calverley P,
   7. et al

   . Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for chronic obstructive pulmonary disease (GOLD). Workshop summary Am J Respir Crit Care Med 2007;176(6):532–555.

   OpenUrl
2. 2.↵
   1. Tashkin DP,
   2. Celli B,
   3. Decramer M,
   4. Liu D,
   5. Burkhart D,
   6. Cassino C,
   7. Kesten S

   . Bronchodilator responsiveness in patients with COPD. Eu Respir J 2008;31(4):742–750.

   OpenUrl
3. 3.↵
   1. Gibson PG,
   2. Simpson JL

   . The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64(8):728–735.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Papi A,
   2. Romagnoli M,
   3. Baraldo S,
   4. Braccioni F,
   5. Guzzinati I,
   6. Saetta M,
   7. et al

   . Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chornic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162(5):1773–1777.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Halpin D,
   2. Peterson S,
   3. Larsson T,
   4. Calverly P

   . Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data. Respir Med 2008;102(11):1615–1624.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Brutsche MH,
   2. Downs SH,
   3. Schindler C,
   4. Gerbase MW,
   5. Schwartz J,
   6. Frey M,
   7. et al

   . Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study. Thorax 2006;61(8):671–677.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Hospers J,
   2. Postma D,
   3. Rijcken B,
   4. Weiss ST,
   5. Schouten J

   . Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000;356(9238):1313–1317.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Leigh R,
   2. Pizzichini MMM,
   3. Morris MM,
   4. Maltais F,
   5. Hargreave FE,
   6. Pizzichini E

   . Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27(5):964–971.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Mahler DA,
   2. Wire P,
   3. Horstman D,
   4. Chang Ch,
   5. Yates J,
   6. Fischer T,
   7. Shah T

   . Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166(8):1084–1091.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Welte T,
    2. Miravitlles M,
    3. Hernandez P,
    4. Eriksson G,
    5. Peterson S,
    6. Polanowski T,
    7. Kessler R

    . Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(8):741–750.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Ries AL,
    2. Bauldoff GS,
    3. Carlin BW,
    4. Casaburi R,
    5. Emery CF,
    6. Mahler DA,
    7. et al

    . Pulmonary Rehabilitation. Joint ACCR/AACVPR evidence-based clinical practice guidelines. Chest 2007;131(5 suppl):S4–S42.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Ortega F,
    2. Toral J,
    3. Cejudo P,
    4. Villagomez R,
    5. Sánchez H,
    6. Castillo J,
    7. Montemayor T

    . Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166(5):669–674.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    American Thoracic Society. Lung function testing; selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144(5):1202–1218.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report 2010. http://www.ginasthma.org/documents/5/documents_variants/35. Accessed November 4, 2013.
15. 15.↵
    1. Pellegrino R,
    2. Viegi G,
    3. Brusasco V,
    4. Crapo RO,
    5. Burgos F,
    6. Casaburi R,
    7. et al

    . Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948–968.

    OpenUrlFREE Full Text
16. 16.↵
    American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167(2):211–277.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Maltais F,
    2. Leblanc P,
    3. Jobin J,
    4. Berube C,
    5. Bruneau J,
    6. Carrier L,
    7. et al

    . Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155(2):555–561.

    OpenUrlPubMedWeb of Science
18. 18.↵
    Recomendaciones de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Normativa para la espirometría forzada. Barcelona: Ed. Doyma; 1985. Article in Spanish.
19. 19.↵
    1. Goldman HI,
    2. Becklake MR

    . Respiratory function test. Normal values at median attitudes and the prediction on normal results. Am Rev Tub 1959;79(4):457–467.

    OpenUrl
20. 20.↵
    1. Celli BR,
    2. Cote CG,
    3. Marin JM,
    4. Casanova C,
    5. Montes de Oca M,
    6. Mendez RA,
    7. et al

    . The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005–1012.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Ortega F,
    2. Montemayor T,
    3. Sanchez A,
    4. Cabello F,
    5. Castillo J

    . Role of cardiopulmonary exercise testing and the criteria used to determine disability in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150(3):747–751.

    OpenUrlPubMedWeb of Science
22. 22.↵
    1. Ward SA,
    2. Palange P

    . Clinical exercise testing. European respiratory monograph. Plymouth, UK: ERS; 2007.
23. 23.↵
    1. Altose MD

    . Assessment and management of breathlessness. Chest 1985;88(2 Suppl):S77–S83.

    OpenUrlPubMed
24. 24.↵
    1. Singh SJ,
    2. Morgan MD,
    3. Scott S,
    4. Walters D,
    5. Hardman AE

    . Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992;47(12):1019–1024.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Lillegard WA,
    2. Terrio JD

    . Appropriate strength training. Med Clin North Am 1994;78(2):457–477.

    OpenUrlPubMedWeb of Science
26. 26.↵
    1. Mahler DA,
    2. Weinberg DH,
    3. Wells CK,
    4. Feinstein AR

    . The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85(6):751–758.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Sweer L,
    2. Zwillich CW

    . Dyspnea in the patient with chronic obstructive pulmonary: etiology and management. Clin Chest Med 1990;11(3):417–445.

    OpenUrlPubMedWeb of Science
28. 28.↵
    1. Guyatt GH,
    2. Berman LB,
    3. Townsend M,
    4. Pugsley SO,
    5. Chambers LW

    . A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42(10):733–778.

    OpenUrl
29. 29.↵
    1. Guell R,
    2. Casan P,
    3. Sangenis M,
    4. Sentís J,
    5. Morante F,
    6. Borras JM,
    7. Guyatt G

    . The Spanish translation and evaluation of a quality-of-life questionnaire in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 1995;31(5):202–210.

    OpenUrlPubMed
30. 30.↵
    1. Han MK,
    2. Agustí A,
    3. Calverley PM,
    4. Celli BR,
    5. Criner G,
    6. Curits JL,
    7. et al

    . Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182(5):598–604.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Shaw DE,
    2. Berry MA,
    3. Hargadon B,
    4. McKenna S,
    5. Shelley Mj,
    6. Green RH,
    7. et al

    . Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007;132(6):1871–1875.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Crapo RO,
    2. Casaburi R,
    3. Coates AL,
    4. Enright PL,
    5. Hankinson JL,
    6. Irvin CG,
    7. et al

    . Guidelines for methacholine and exercise challenge testing—1999. Am J Respir Crit Care Med 2000;161(1):309–329.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Brouillard C,
    2. Pepin V,
    3. Milot J,
    4. Lacasse Y,
    5. Maltais F

    . Endurance shuttle walking test: responsiveness to salmeterol in COPD. Eur Respir J 2008;31(3):579–584.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Pepin V,
    2. Saey D,
    3. Whittom F,
    4. LeBlanc P,
    5. Maltais F

    . Walking versus cycling. Sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172(12):1517–1522.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. Pepin V,
    2. Brodeur J,
    3. Lacasse Y,
    4. Milot J,
    5. LeBlanc P,
    6. Whittom F,
    7. Maltais F

    . Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease. Thorax 2007;62(4):291–298.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Singh SJ,
    2. Jones PW,
    3. Evans R,
    4. Morgan MDL

    . Minimum clinically important improvement for the incremental shuttle walking test. Thorax 2008;63(9):775–7.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Oga T,
    2. Nishimura K,
    3. Tsukino M,
    4. Sato S,
    5. Hajiro T

    . Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167(4):544–549.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Cote CG,
    2. Pinto-Plata V,
    3. Kasprzyk K,
    4. Dordelly LJ,
    5. Celli BR

    . The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest 2007;132(6):1778–1785.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Calverley PM,
    2. Burge PS,
    3. Spencer S,
    4. Anderson JA,
    5. Jones PW

    . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58(8):659–664.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Hurst JR,
    2. Vestbo J,
    3. Anzueto A

    . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128–1138.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. de Torres JP,
    2. Pinto-Plata V,
    3. Ingenito E,
    4. Bagley P,
    5. Gray A,
    6. Berger R,
    7. Celli B

    . Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002;121(4):1092–8.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Johannessen A,
    2. Lehmann S,
    3. Omenaas ER,
    4. Eide GE,
    5. Bakke PS,
    6. Gulsvik A

    . Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 2006;173(12):1316–1325.

    OpenUrlCrossRefPubMedWeb of Science